https://doi.org/10.4081/mem.2008.286

RU486: aspetti farmacologici e tossicologici

Vol. 57 No. 2 (2008)
Published: April 30, 2008
RU486, misoprostolo, aborto chimico / RU486, misoprostol, chemical abortion
Abstract Views: 510
PDF (Italiano): 4
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

L. Romano
lucioromano@libero.it
Dirigente Ginecologo Dipartimento di Scienze Ostetrico Ginecologiche, Urologiche e Medicina della Riproduzione, Università degli Studi di Napoli "Federico II", Dottore di Ricerca in Bioetica, Italy.
M.L. Di Pietro
Professore Associato di Bioetica, Università Cattolica del Sacro Cuore, Roma, Italy.
M.R. Vitelli
Dottore di Ricerca in Farmacologia, Italy.
L. Berrino
Professore Ordinario di Farmacologia, Sezione di Farmacologia Dipartimento di Medicina Sperimentale, II Università degli Studi di Napoli, Italy.
Il ricorso al mifepristone (RU486), in combinazione con analoghi delle prostaglandine, nell'induzione dell'aborto chimico richiede una specifica riflessione in merito ai principali aspetti farmacologici e tossicologici. L'attuale dialettica bioetica e biopolitica, spesso ideologizzata, impone ancor più una trattazione rigorosa basata sulle evidenze scientifiche, a chiarimento soprattutto dei meccanismi d'azione e degli eventi avversi. Questi ultimi a volte anche sottodimensionati o minimizzati. Premessa l'iniquità dell'aborto volontario, l'articolo si prefigge anche lo scopo di chiarire come, in ordine ai dati della più recente bibliografia, il ricorso all'RU486 rappresenti un significativo rischio per la salute delle donne. Una particolare attenzione è riservata alla chiarificazione etiopatogenetica delle emorragie e delle sepsi, dalle quali si sono riscontrati anche diversi decessi. Nell'articolo sono riportati, inoltre, i più attuali sviluppi della ricerca con RU486 sia per il trattamento sperimentale di patologie - ginecologiche e non - che per l'uso della molecola per la contraccezione ormonale e la "contraccezione di emergenza".
----------
The use of mifepristone (RU486), in combination with prostaglandin analogues, in the chemical abortion, requires a specific reflection on the main aspects in pharmacology and toxicology. The current debate in bioethics and biopolitical, often ideological, imposes a more rigorous treatment based on scientific evidences, especially clarification of the mechanisms of action and severe adverse events. The latter sometimes underestimated or minimized. Declared beforehand the iniquity of volunteer abortion, this article aims also to clarify how, in order to the data from the most recent literature, the use of RU486 represents a significant risk to women's health. Particular attention is given to etiopathogenetic clarification of bleeding and sepsis, which have also seen several deaths. The article reportes, moreover, the most current developments in the research for RU486 treatment of experimental conditions - gynaecological and not - and for the use of the molecule in the hormonal contraception and the "emergency contraception".

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Romano, L., Di Pietro, M., Vitelli, M., & Berrino, L. (2008). RU486: aspetti farmacologici e tossicologici. Medicina E Morale, 57(2). https://doi.org/10.4081/mem.2008.286

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

An Open Access Publication is one that meets the following two conditions:

  1. the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
  2. a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.